On December 5, CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, announced that George A. Komatsoulis, Ph.D., will be its first Chief of Bio-Informatics. This marks another step toward the organization’s goal of making the CancerLinQ® platform the premier system for unlocking patient data from millions of electronic health records (EHR), breaking down silos among various EHR systems and providers, and securely processing and analyzing the data to give personalized insights than can improve the quality of care for patients with cancer.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
“Today, by passing the 21st Century Cures Act, the U.S. House of Representatives took a significant step forward to accelerate the pace of bringing promising new treatments to patients—including the 1.6 million Americans diagnosed with cancer each year. The American Society of Clinical Oncology (ASCO) commends the passage of the Cures Act by the House and urges the U.S. Senate to support and send this landmark legislation to the President for his signature.”
On November 30, CancerLinQ LLC, a nonprofit subsidiary of ASCO, announced CancerLinQ Discovery™, a groundbreaking offering that will provide insights through the analysis of real-world cancer care data.
ASCO has developed a new program designed to improve the delivery of cancer care in medically underserved communities by increasing access of participating practices to ASCO’s quality improvement resources.
On November 29, DCInno announced its 12 finalists in the Health and Medicine category of the “50 on Fire” awards, and CancerLinQ LLC Chief of Strategic Alliances Jennifer L. Wong was one of the individuals selected.
President-elect Donald Trump has announced his plan to nominate Representative Tom Price (R-GA) as Secretary of the Department of Health and Human Services (HHS) and Seema Verma as Administrator of the Centers for Medicare and Medicaid Services (CMS).
ASCO and the College of American Pathologists have been working together for a decade on efforts to optimize care for patients with cancer by fostering excellence in the practices of pathology and oncology. In 2014, the two societies formalized their collaboration to work together in a number of mutually important areas to advance high-quality care.
ASCO has released, "Criteria for High-Quality Clinical Pathways in Oncology," a set of 15 inter-related criteria that provide an overarching framework for assessing pathway programs in the United States. ASCO developed the criteria to guide stakeholders in assessing the quality, utility and integrity of clinical pathways in oncology.
ASCO urged Members of Congress to vote "Yes" on the 21st Century Cures Act, which would help accelerate the discovery, development, and delivery of promising treatments to patients.
Though Congress has adjourned for the Thanksgiving holiday, ASCO continues to monitor important cancer policy issues in the waning days of the 2016 lame duck session.
On November 21, 2016, the U.S. Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
ASCO and the Oncology Nursing Society (ONS) have updated their chemotherapy administration safety standards to include pediatric oncology care. The updated standards can be found in the Journal of Oncology Practice.
On November 21, the online news source HIT Leaders & News featured an article about the evolution of CancerLinQ® and how ASCO’s rich history of a commitment to quality and quest for knowledge served as a foundation for the platform.
In November, the President’s Cancer Panel released a report, “Improving Cancer-Related Outcomes with Connected Health,” which presents goals and recommendations to advance the use of connected health for cancer care; both ASCO and its CancerLinQ platform were mentioned in the report.
More than 100 participants are now enrolled on study drug in the ASCO® Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The trial launched in March 2016 at 37 sites and this month welcomes its newest participating clinical sites: Cancer Treatment Centers of America®, Intermountain Healthcare, Sanford Health, Swedish Cancer Institute and Providence Health & Services, and University of Nebraska Medical Center for a total of 63 participating sites in 15 states.